The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Trevi Therapeutics (TRVI) has seen a significant surge in institutional interest, with F m Investments LLC establishing a new position by purchasing 241,483 shares valued at approximately $3.0 million. Simultaneously, Comerica Bank aggressively increased its stake in TRVI by 19,481.8%, bringing its total position to $1.04 million. This bullish trend is supported by positive analyst sentiment and upward revisions in earnings estimates for the biotech firm. Conversely, F m Investments LLC reduced its exposure to Stryker Corporation (SYK) by 66.4% during the fourth quarter. The reduction follows mixed quarterly results from SYK that missed market estimates, prompting a rotation of capital. These portfolio adjustments highlight a strategic shift among institutional players toward high-growth healthcare opportunities.
Sign in to access this content
Sign In